¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ i+vsp@d  
%i0\1hhV<  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© -w 6 "?  
E;(Rm>lB  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© xi'>mIT  
~,gXaw  
1.Co-stimulators (or co-stimulating molecules) tiaR4PB  
)@g;j>  
2.NK-kB DPDe>3Mi[  
uOi&G:=  
3.Immunoglobulin superfamily -V<t-}h.  
' /%zi,0  
4.antigen-presenting cell (APC) NeOxpn[  
I=Zx"'Um  
5.death domain $p* p  
@ GDX7TPV  
6.CCR and CXCR %Z]'!X  
'3(l-nPiG^  
7.Lectin (or mitogen) pxINw> \Qv  
Xa 9TS"  
8.Clusters of differentiation, CD) (jWss  V1  
j . A6S`  
9.B7 family R4's7k  
h5zVGr  
10.Cytotoxic T lymphocyte, CTL) Wsj=!Obc  
dKhA$f~  
11.IL-15 and IL-15 receptor (IL-15R) !Jfs?Hy  
9ptFG]lZ  
12.MHC restriction H}0dd"  
,d,\-x-+/  
13.Affinity-chromatography S[:xqzyDg  
"E=j|q  
14.Cyctosprin A, CsA vR7HF*8  
T6 #"8qz<  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) [Gr*,nVvB  
2s ,8R  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© mz7l'4']+  
2h^WYpCm  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ,Fqz e/  
ZFh+x@  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ Yn51U6_S  
=(r* 5vd  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ &x:JD1T}  
l0]d  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© f>Td)s1 M  
eo]#sf@\0  
ÃâÒßѧרҵ£º %Q|eiXD  
" BTE  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ Al"3 kRJJ  
E;\M1(\u  
Ïû»¯ÄÚ¿Æ£º Eh8Pwt7C@  
]5CNk+`'  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ ;1AG3P'  
i\}:hU-U  
ѪҺ²¡Ñ§×¨Òµ£º |lQ;ALH!  
>O`l8tM  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»